• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医院内 COVID-19 死亡的相关因素:回顾性死亡率数据的竞争风险生存时间分析。

Correlates of In-Hospital COVID-19 Deaths: A Competing Risks Survival Time Analysis of Retrospective Mortality Data.

机构信息

Department of Medicine, UCMS and GTB Hospital, Delhi.

Hamdard Institute of Medical Sciences and Research, New Delhi, India.

出版信息

Disaster Med Public Health Prep. 2022 Oct;16(5):1889-1896. doi: 10.1017/dmp.2021.85. Epub 2021 Mar 25.

DOI:10.1017/dmp.2021.85
PMID:33762056
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8129688/
Abstract

INTRODUCTION

Several aspects of the coronavirus disease 2019 (COVID-19) pandemic remain ambiguous, including its transmission, severity, geographic, and racial differences in mortality. These variations merit elaboration of local patterns to inform wider national policies.

METHODS

In a retrospective analysis, data of patients treated at a dedicated COVID hospital with moderate and severe illness during 8 wk of the pandemic were reviewed with attention to mortality in a competing risks framework.

RESULTS

A total of 1147 patients were hospitalized, and 312 (27.2%) died in hospital. Those who died were older (56.5 vs 47.6 y; < 0.0001). Of these, 885 (77.2%) had tested positive on reverse transcriptase polymerase chain reaction (RT-PCR), with 219 (24.2%) deaths (incidence rate, 1.9 per 100 person-days). Median time from onset of symptoms to death was 11 days. A competing risks analysis for revealed an adjusted cause-specific hazard ratio of 1.4 for each decade increase in age.

CONCLUSIONS

This retrospective analysis provides broad patterns of disease presentation and mortality. Even COVID test-negative patients will receive treatment at dedicated facilities, and 33% presenting cases may die within the first 72 h, most with comorbid illness. This should be considered while planning distribution of services for effective health-care delivery.

摘要

简介

新冠病毒病(COVID-19)大流行仍有许多不明之处,包括其传播、严重程度、地理和种族差异导致的死亡率。这些差异值得对当地模式进行阐述,以告知更广泛的国家政策。

方法

在一项回顾性分析中,对一家专门的 COVID 医院在大流行的 8 周内收治的中度和重度疾病患者的数据进行了回顾,重点关注竞争风险框架下的死亡率。

结果

共有 1147 名患者住院,312 名(27.2%)在医院死亡。死亡患者年龄较大(56.5 岁比 47.6 岁;<0.0001)。其中,885 名(77.2%)经逆转录酶聚合酶链反应(RT-PCR)检测呈阳性,219 名(24.2%)死亡(发病率为每 100 人-日 1.9 人)。从症状发作到死亡的中位时间为 11 天。对 进行竞争风险分析表明,年龄每增加 10 岁,调整后的特定病因危险比为 1.4。

结论

这项回顾性分析提供了疾病表现和死亡率的广泛模式。即使是 COVID 检测阴性的患者也将在专门的设施接受治疗,33%的就诊病例可能在最初的 72 小时内死亡,其中大多数伴有合并症。在规划服务分配以有效提供医疗服务时,应考虑这一点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/4fdc2291200e/S1935789321000859_fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/836993ae2488/S1935789321000859_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/3da2a7729190/S1935789321000859_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/712f88d0d168/S1935789321000859_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/9de39e0866d9/S1935789321000859_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/a9676dc20c60/S1935789321000859_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/75aebb5ff099/S1935789321000859_fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/856718ada095/S1935789321000859_fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/28e6dab30177/S1935789321000859_fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/4fdc2291200e/S1935789321000859_fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/836993ae2488/S1935789321000859_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/3da2a7729190/S1935789321000859_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/712f88d0d168/S1935789321000859_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/9de39e0866d9/S1935789321000859_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/a9676dc20c60/S1935789321000859_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/75aebb5ff099/S1935789321000859_fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/856718ada095/S1935789321000859_fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/28e6dab30177/S1935789321000859_fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f58/8129688/4fdc2291200e/S1935789321000859_fig9.jpg

相似文献

1
Correlates of In-Hospital COVID-19 Deaths: A Competing Risks Survival Time Analysis of Retrospective Mortality Data.医院内 COVID-19 死亡的相关因素:回顾性死亡率数据的竞争风险生存时间分析。
Disaster Med Public Health Prep. 2022 Oct;16(5):1889-1896. doi: 10.1017/dmp.2021.85. Epub 2021 Mar 25.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
4
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.癌症患者出现 COVID-19 症状,无论 RT-PCR 是否检测到 SARS-COV-2,死亡率均较高。
Eur J Cancer. 2020 Aug;135:251-259. doi: 10.1016/j.ejca.2020.05.028. Epub 2020 Jun 7.
5
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019(COVID-19)的病理生理学、传播、诊断和治疗:综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
6
Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19.严重 COVID-19 适应性风险预测器(SCARP)的开发,是一种用于预测 COVID-19 住院患者发生严重疾病或死亡的计算器。
Ann Intern Med. 2021 Jun;174(6):777-785. doi: 10.7326/M20-6754. Epub 2021 Mar 2.
7
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.意大利伦巴第地区 1591 名 ICU 收治的 SARS-CoV-2 感染患者的基线特征和结局。
JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394.
8
Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.重症监护治疗新型冠状病毒 SARS-CoV-2 感染患者:意大利克雷马医院的经验。
Am J Emerg Med. 2021 Jul;45:156-161. doi: 10.1016/j.ajem.2020.08.005. Epub 2020 Aug 16.
9
Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.斋浦尔市522例COVID-19住院患者的羟氯喹特性、治疗结果及作用:一项流行病学临床研究
J Assoc Physicians India. 2020 Jun;68(6):13-19.
10
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.挪威 2019 年冠状病毒病(NO COVID-19)实用开放性标签研究,评估硫酸羟氯喹在 2019 年冠状病毒病中度重症住院患者中的早期使用:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):485. doi: 10.1186/s13063-020-04420-0.

引用本文的文献

1
Long-Term Persistence of COVID-Induced Hyperglycemia: A Cohort Study.COVID 相关高血糖的长期持续存在:一项队列研究。
Am J Trop Med Hyg. 2024 Feb 13;110(3):512-517. doi: 10.4269/ajtmh.22-0695. Print 2024 Mar 6.
2
Handling death as an intercurrent event in time to recovery analysis in COVID-19 treatment clinical trials.将死亡作为 COVID-19 治疗临床试验中时间到恢复分析的伴随事件进行处理。
Contemp Clin Trials. 2022 Aug;119:106758. doi: 10.1016/j.cct.2022.106758. Epub 2022 Apr 6.
3
Comprehensive evaluation of COVID-19 patient short- and long-term outcomes: Disparities in healthcare utilization and post-hospitalization outcomes.

本文引用的文献

1
Profile of Patients Suspected to be COVID-19: A Retrospective Analysis of Early Pandemic Data.疑似新型冠状病毒肺炎患者的特征:大流行早期数据的回顾性分析
Cureus. 2020 Aug 29;12(8):e10125. doi: 10.7759/cureus.10125.
2
Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy.意大利米兰 COVID-19 急性呼吸窘迫综合征有创通气患者的特征、治疗、结局和死亡原因。
Crit Care Resusc. 2020 Sep;22(3):200-211. doi: 10.1016/S1441-2772(23)00387-3.
3
Defining heart disease risk for death in COVID-19 infection.
COVID-19患者短期和长期预后的综合评估:医疗保健利用和出院后预后的差异
PLoS One. 2021 Oct 6;16(10):e0258278. doi: 10.1371/journal.pone.0258278. eCollection 2021.
定义 COVID-19 感染导致死亡的心脏病风险。
QJM. 2020 Dec 1;113(12):876-882. doi: 10.1093/qjmed/hcaa246.
4
Blood type A associates with critical COVID-19 and death in a Swedish cohort.在瑞典一个队列中,A型血与重症新冠病毒疾病及死亡相关。
Crit Care. 2020 Aug 12;24(1):496. doi: 10.1186/s13054-020-03223-8.
5
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19.白菜和发酵蔬菜:从各国死亡率的差异看严重 COVID-19 缓解策略的候选者。
Allergy. 2021 Mar;76(3):735-750. doi: 10.1111/all.14549. Epub 2020 Sep 15.
6
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain.西班牙 4035 例连续住院 COVID-19 患者的死亡特征和预测因素。
Clin Microbiol Infect. 2020 Nov;26(11):1525-1536. doi: 10.1016/j.cmi.2020.07.024. Epub 2020 Aug 4.
7
Dying 'due to' or 'with' COVID-19: a cause of death analysis in hospitalised patients.因 COVID-19 而死亡或与 COVID-19 共同导致死亡:住院患者死因分析。
Clin Med (Lond). 2020 Sep;20(5):e189-e190. doi: 10.7861/clinmed.2020-0440. Epub 2020 Aug 3.
8
Association of Comorbidities With Pneumonia and Death Among COVID-19 Patients in Mexico: A Nationwide Cross-sectional Study.墨西哥COVID-19患者合并症与肺炎及死亡的关联:一项全国性横断面研究。
J Prev Med Public Health. 2020 Jul;53(4):211-219. doi: 10.3961/jpmph.20.186. Epub 2020 May 28.
9
Increased Risk of Hospitalization and Death in Patients with COVID-19 and Pre-existing Noncommunicable Diseases and Modifiable Risk Factors in Mexico.墨西哥患有 COVID-19 及既往非传染性疾病和可改变的危险因素的患者住院和死亡风险增加。
Arch Med Res. 2020 Oct;51(7):683-689. doi: 10.1016/j.arcmed.2020.07.003. Epub 2020 Jul 22.
10
Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy.意大利撒丁岛住院 COVID-19 患者的临床特征、实验室检查结果和死亡预测因素。
Eur Rev Med Pharmacol Sci. 2020 Jul;24(14):7861-7868. doi: 10.26355/eurrev_202007_22291.